|
Volumn 9, Issue 19, 2004, Pages 826-827
|
Multitargeted drugs: The end of the 'one-target-one-disease' philosophy?
|
Author keywords
AIDS tritherapy; Chemical Biology; Cytokine regulator; Drug Discovery; Ligands; Parkinson's disease; Pharmaceutical Science; Pharmacophore
|
Indexed keywords
ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT;
AMOXICILLIN;
AMOXICILLIN PLUS CLAVULANIC ACID;
ANTINEOPLASTIC AGENT;
BETA LACTAMASE INHIBITOR;
CATECHOL METHYLTRANSFERASE INHIBITOR;
CELECOXIB;
CLAVULANIC ACID;
CLOZAPINE;
CYCLOOXYGENASE 2 INHIBITOR;
CYTOKINE;
DOPA;
DOPA DECARBOXYLASE INHIBITOR;
DOPAMINE 2 RECEPTOR;
IMATINIB;
INTERLEUKIN 10;
PHOSPHODIESTERASE V INHIBITOR;
PROTEINASE INHIBITOR;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
SEROTONIN 1 RECEPTOR;
SEROTONIN 1A RECEPTOR;
SEROTONIN 2 RECEPTOR;
SILDENAFIL;
TAMSULOSIN;
TUMOR NECROSIS FACTOR ALPHA;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
DRUG ACTIVITY;
HUMAN;
PARKINSON DISEASE;
PHARMACOPHORE;
SHORT SURVEY;
VIRUS INFECTION;
|
EID: 4644289587
PISSN: 13596446
EISSN: None
Source Type: Journal
DOI: 10.1016/S1359-6446(04)03213-1 Document Type: Note |
Times cited : (99)
|
References (7)
|